TICON-Day 3, Time Lapse Versus Conventional Method in Day 3 Embryo Culture and Assessment
Launched by MERCK KGAA, DARMSTADT, GERMANY · May 22, 2017
Trial Information
Current as of May 03, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Couples with less than or equal to (\<= ) two failed fresh In Vitro Fertilization/Intracytoplasmic Sperm Injection (IVF/ICSI) embryo transfer cycles
- • Age greater than or equal to (\>=) 18 and \<= 40 years
- • Body mass index (BMI): 18-30 kilogram per meter square (kg/m2)
- • Normal uterine cavity under ultrasound
- • Participant and her husband/partner must have read and signed the Informed Consent form (ICF)
- • At least four normally fertilized oocytes (2Pronuclear stage (PN)) in the current cycle
- Exclusion Criteria:
- • Male with non-ejaculated sperm
- • Participants with abnormal, undiagnosed gynecological bleeding or with genitourinary malformations
- • Participants with any contraindication to Controlled Ovarian Stimulation (COS) for Assisted Reproductive Technologies (ART) or to gonadotropins
- • Planned "freeze all" cycle (oocytes or embryos)
- • Planned preimplantation genetic screening (PGS) or Pre-implantation genetic diagnosis (PGD) cycle
- • Concurrent participation in another clinical study
About Merck Kgaa, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, is a leading global science and technology company, specializing in healthcare, life sciences, and performance materials. With a rich history dating back to 1668, Merck KGaA is committed to advancing innovative solutions that improve the quality of life for patients and drive scientific discovery. The company invests significantly in research and development to bring cutting-edge therapies to market, focusing on areas such as oncology, immunology, and neurology. As a dedicated clinical trial sponsor, Merck KGaA collaborates with healthcare professionals and institutions worldwide to conduct rigorous trials that ensure the safety and efficacy of its products, ultimately aiming to enhance patient outcomes and foster global health advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Clamart, , France
Granada, , Spain
Oslo, , Norway
Baracaldo, , Spain
Skive, , Denmark
Calgary, , Canada
Calgary, , Canada
Skive, , Denmark
Bruneck (Bz), , Italy
Firenze, , Italy
Firenze, , Italy
Viareggio, , Italy
Skien, , Norway
Trodheim, , Norway
Coimbra, , Portugal
Barcelona, , Spain
Santa Cruz De Tenerife, , Spain
Patients applied
Trial Officials
Medical Responsible
Study Director
Merck KGaA, Darmstadt, Germany
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials